Collegium Pharmaceutical (NASDAQ:COLL) Sets New 1-Year Low – Here’s Why

Collegium Pharmaceutical, Inc. (NASDAQ:COLL)’s share price hit a new 52-week low on Friday . The stock traded as low as $25.46 and last traded at $25.54, with a volume of 290193 shares. The stock had previously closed at $26.44.

Analyst Ratings Changes

A number of equities research analysts have commented on COLL shares. Weiss Ratings cut Collegium Pharmaceutical from a “hold (c)” rating to a “hold (c-)” rating in a report on Tuesday, August 11th. Wall Street Zen lowered Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Needham & Company LLC cut their target price on Collegium Pharmaceutical from $56.00 to $46.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. Barclays decreased their target price on Collegium Pharmaceutical from $56.00 to $48.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 19th. Finally, Zacks Research cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 28th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, Collegium Pharmaceutical currently has an average rating of “Moderate Buy” and a consensus price target of $51.00.

Collegium Pharmaceutical Price Performance

The firm has a market cap of $832.23 million, a P/E ratio of 20.61 and a beta of 0.73. The firm’s fifty day simple moving average is $33.12 and its 200 day simple moving average is $35.13. The company has a debt-to-equity ratio of 3.32, a quick ratio of 0.84 and a current ratio of 1.03.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 EPS for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%.The company had revenue of $199.88 million for the quarter, compared to the consensus estimate of $199.62 million. During the same period in the previous year, the business earned $1.68 earnings per share. The firm’s revenue for the quarter was up 6.3% on a year-over-year basis. As a group, analysts forecast that Collegium Pharmaceutical, Inc. will post 6.51 earnings per share for the current year.

Institutional Trading of Collegium Pharmaceutical

Hedge funds have recently modified their holdings of the company. Vident Advisory LLC boosted its position in shares of Collegium Pharmaceutical by 1.9% during the 3rd quarter. Vident Advisory LLC now owns 15,466 shares of the specialty pharmaceutical company’s stock valued at $541,000 after acquiring an additional 281 shares during the last quarter. Quadrant Capital Group LLC increased its position in Collegium Pharmaceutical by 4.2% in the fourth quarter. Quadrant Capital Group LLC now owns 6,996 shares of the specialty pharmaceutical company’s stock worth $324,000 after purchasing an additional 282 shares during the last quarter. Atom Investors LP increased its position in Collegium Pharmaceutical by 5.0% in the fourth quarter. Atom Investors LP now owns 6,124 shares of the specialty pharmaceutical company’s stock worth $284,000 after purchasing an additional 294 shares during the last quarter. Assetmark Inc. raised its stake in Collegium Pharmaceutical by 9.3% during the first quarter. Assetmark Inc. now owns 3,923 shares of the specialty pharmaceutical company’s stock valued at $130,000 after purchasing an additional 335 shares in the last quarter. Finally, ProShare Advisors LLC lifted its position in Collegium Pharmaceutical by 5.0% during the fourth quarter. ProShare Advisors LLC now owns 7,507 shares of the specialty pharmaceutical company’s stock valued at $348,000 after purchasing an additional 356 shares during the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.